NCT03478254 (AVADI-1) is a clinical trial of Influenza vaccination in Type 1 Diabetes Mellitus, sponsored by Jesús Moreno Fernández.

Who is sponsoring NCT03478254?

NCT03478254 is sponsored by Jesús Moreno Fernández.

What drugs are being tested in NCT03478254?

Interventions in NCT03478254: Influenza vaccination, Pneumococcal vaccination, Hepatitis B Virus (HBV) vaccination.

What condition does NCT03478254 study?

NCT03478254 studies Type 1 Diabetes Mellitus.

Is NCT03478254 still recruiting?

NCT03478254 is currently completed. Last updated 11 January 2021.

Are results published for NCT03478254?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-01-11 · How we verify

NCT03478254: AVADI-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).

Completed Results posted Last updated 11 January 2021

What this trial tests

trial testing Influenza vaccination in Type 1 Diabetes Mellitus in 300 participants. Completed in 31 December 2018.

Timeline

1 December 2017

Primary endpoint
1 December 2018

31 December 2018

Quick facts

Lead sponsor	Jesús Moreno Fernández
Status	Completed
Study type	OBSERVATIONAL
Enrollment	300
Start date	1 December 2017
Primary completion	1 December 2018
Estimated completion	31 December 2018
Sites	1 location across Spain

Drugs / interventions tested

Influenza vaccination — full drug profile →
Pneumococcal vaccination — full drug profile →
Hepatitis B Virus (HBV) vaccination — full drug profile →

Conditions studied

Type 1 Diabetes Mellitus — all drugs for Type 1 Diabetes Mellitus →

Sponsor

Jesús Moreno Fernández — full company profile →

Who can join

18 and older, any sex, with Type 1 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Adherence to Regional Guidelines for the Immunization of Adults With Type 1 Diabetes Mellitus (T1DM Primary · 1 year

Adherence to Influenza, Pneumococcal and Hepatitis B Vaccination in adult patients with type 1 Diabetes mellitus.

Group	Value	95% CI
Adherece Vaccination	165
Adherece Vaccination	54
Adherece Vaccination	51
Adherece Vaccination	30

Patient Age According to Vaccination Status Secondary · 1 year

Age (years)

Age : Influenzae vaccination:

Group	Value	95% CI
Adherece Vaccination	43.5	± 15.2

Age : No influcenzae vaccination

Group	Value	95% CI
Adherece Vaccination	39.7	± 13.0

Age : HBV vaccination

Group	Value	95% CI
Adherece Vaccination	28.3	± 10.8

Age : HBV pneumoccocal vaccination

Group	Value	95% CI
Adherece Vaccination	44.5	± 13.5

Number of Participants Who Have Taken Related Sick Leaves Secondary · 1 year

Number of patients who have taken related sick leaves.

Group	Value	95% CI
Vaccination Adherence	17

Sponsor's own description

Observational study about adherence to guidelines for Influenza, Pneumococcal and Hepatitis B Vaccination in adult patients with type 1 Diabetes mellitus.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Vaccination adherence to influenza, pneumococcal and hepatitis B virus in adult type 1 diabetes mellitus patients.
Moreno-Fernández J, García-Seco JA, Rodrigo EMO, Segura AMS, et al · · 2020 · cited 6× · PMID 31582202 · DOI 10.1016/j.pcd.2019.09.004

Verify or expand the search:

Other trials of Influenza vaccination

Trials testing the same drug.

NCT05481801 — Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2) · completed
NCT04188483 — Effect of Selenium Supplementation on Influenza Vaccination · NA · completed
NCT03590808 — Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor · NA · completed
NCT03346772 — Study of Immune Responses to Influenza Vaccination · Phase 4 · recruiting

Other recruiting trials for Type 1 Diabetes Mellitus

Currently open trials in the same condition.

NCT07142252 — Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus · Phase 2 · recruiting
NCT07296276 — Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM · NA · recruiting
NCT07409701 — Gamification Intervertion in Children With Type 1 Diabetes · NA · recruiting
NCT07356089 — Twiist Postmarket Surveillance Study for Type 1 Diabetes · recruiting
NCT07434154 — Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults · recruiting

Other Jesús Moreno Fernández trials

Trials by the same sponsor.

NCT04233203 — Faster Aspart on Insulin-pump Treated T1DM Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03478254 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jesús Moreno Fernández
Last refreshed: 11 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03478254.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing